Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations
Open Access
- 19 August 2013
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (36) , 14747-14752
Abstract
Integration of the DNA copy of the HIV-1 genome into a host chromosome is required for viral replication and is thus an important target for antiviral therapy. The HIV-encoded enzyme integrase (IN) catalyzes two essential steps: 3′ processing of the viral DNA ends, followed by the strand transfer reaction, which inserts the viral DNA into host DNA. Raltegravir binds to IN and blocks the integration of the viral DNA. Using the Rous sarcoma virus-derived vector RCAS, we previously showed that mutations that cause one viral DNA end to be defective for IN-mediated integration led to abnormal integrations in which the provirus had one normal and one aberrant end, accompanied by rearrangements in the host genome. On the basis of these results, we expected that suboptimal concentrations of IN inhibitors, which could block one of the ends of viral integration, would lead to similar aberrant integrations. In contrast to the proviruses from untreated cells, which were all normal, ∼10–15% of the proviruses isolated after treatment with a suboptimal dose of raltegravir were aberrant. The aberrant integrations were similar to those seen in the RCAS experiments. Most of the aberrant proviruses had one normal end and one aberrant end and were accompanied by significant rearrangements in the host genome, including duplications, inversions, deletions and, occasionally, acquisition of sequences from other chromosomes. The rearrangements of the host DNA raise concerns that these aberrant integrations might have unintended consequences in HIV-1–infected patients who are not consistent in following a raltegravir-containing treatment regimen.Keywords
This publication has 30 references indexed in Scilit:
- HIV-1 Antiretroviral Drug TherapyCold Spring Harbor Perspectives in Medicine, 2012
- Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2011
- Cancer Burden in the HIV-Infected Population in the United StatesJNCI: Journal of the National Cancer Institute, 2011
- Structural insights into the retroviral DNA integration apparatusCurrent Opinion in Structural Biology, 2011
- Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistanceProceedings of the National Academy of Sciences, 2010
- Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 ReplicationJournal of Virology, 2010
- Retroviral intasome assembly and inhibition of DNA strand transferNature, 2010
- Mutations in the U5 Region Adjacent to the Primer Binding Site Affect tRNA Cleavage by Human Immunodeficiency Virus Type 1 Reverse Transcriptase In VivoJournal of Virology, 2008
- Integrase and integration: biochemical activities of HIV-1 integraseRetrovirology, 2008
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994